Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (428)	6/15/1999 9:44:00 AM
From: Biomaven	Read Replies (1) \| Respond to of 3158

The only biotech that I can think of that is actually in clinical trials for obesity is REGN, which may be big enough to cause MLNM some indigestion. (I'm discounting AMGN's foray into Leptin). The whole world's doing inflammation, so that doesn't narrow things down much. Peter

To: scaram(o)uche who wrote (428)	6/15/1999 11:57:00 AM
From: RCMac	Read Replies (2) \| Respond to of 3158

>> I suggested GLIA to an underwriter awhile back, but I just got a guffaw because of the Adcon business (surgical devices). << Why a guffaw? 80-85% gross margins -- in a market that is a bit slow-developing because you have to penetrate surgeons' habits -- not sexy enough? --Bob

To: scaram(o)uche who wrote (428)	6/15/1999 3:35:00 PM
From: LLCF	Read Replies (1) \| Respond to of 3158

<Either NBIX or GLIA would fit great.> NBIX with 5 clinical compounds must look tasty..... Wowa.... look! GLIA's getting tastier as we speak! Jeez $20 on the stock, what happend. Sorry, O.T. just saw it. DAK